SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.
The move came as the drug is regarded as passing the regulator's consistency evaluation.
The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments